Aurora BioPharma, Inc. CEO to Attend the Rodman & Renshaw 2015 Annual Global Investment Conference
CAMBRIDGE, MA - September 7, 2015 - Aurora BioPharma, Inc. announces that its Chief Executive Officer, Robert Brooks, will attend the Rodman & Renshaw 17th Annual Global Investment Conference taking place at the St. Regis Hotel in New York City on September 8 - 10.
The event is expected to attract over 200 presenting public and private companies and over 2,000 industry executives, institutional investors, and venture capitalists. The conference will feature corporate presentations, investor one-on-one meetings, and daily networking discussions devoted to topics including Biotechnology, Healthcare, Cleantech, and Metals and Mining. The 56th Secretary of State of the United States and Nobel Peace Prize laureate, Henry A. Kissinger, will serve as the keynote speaker.
About Aurora BioPharma, Inc.
Aurora is a biotechnology company based in Cambridge, Massachusetts commercializing cutting-edge cancer immunotherapy drugs in FDA human clinical trials. Aurora's portfolio includes: MX-225, an autologous P53 dendritic cell vaccine that completed two Phase IIa trials in Small Cell Lung Cancer (SCLC), and recurring breast cancer. The company is planning a Phase II SCLC combination trial with MX-225 and a PD-1 antibody and developing a car-t therapy. Another one of Aurora's drugs in clinic is MX-402 - a unique B-cell epitope HER-2 Peptide vaccine that had showed safety and strong signals of efficacy in an interim Phase I trial. Eight of twelve patients showed clinical benefit, with one patient in complete remission. Aurora's team is comprised of world renowned scientists and biotech industry professionals.
Cautionary Note on Forward-Looking Statements
This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For media inquiries, please contact:
VP, Business Development & Public Relations
Aurora BioPharma, Inc.
Harvard Square, One Mifflin Place, Suite 400
Cambridge, MA 02138
Tel: 617-674-7718 - Fax: 617-674-7701
Ingraham Building, 25 SE 2nd Avenue, Suite 504
Miami, FL 33131
Tel: 305-371-2301 - Fax: 305-371-2301
firstname.lastname@example.org - www.aurorabiopharma.net
- New Paradigm in Cancer Immunotherapy -
Source: Aurora BioPharma, Inc.